Advertisement
Advertisement
U.S. markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Harrow Health, Inc. (HROW)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
11.81-1.01 (-7.88%)
At close: 04:00PM EDT
11.70 -0.11 (-0.93%)
After hours: 06:48PM EDT
Advertisement

Harrow Health, Inc.

102 Woodmont Boulevard
Suite 610
Nashville, TN 37205
United States
615 733 4730
https://www.harrowinc.com

Sector(s)Healthcare
IndustryDrug Manufacturers—Specialty & Generic
Full Time Employees182

Key Executives

NameTitlePayExercisedYear Born
Mr. Mark L. Baum J.D.CEO & Chairman1.07MN/A1973
Mr. Andrew R. Boll C.F.A., C.M.A., CFA, CMACFO & Corp. Sec.716.73kN/A1982
Dr. Robert J. Kammer D.D.S.Special Advisor91.88kN/A1949
Mr. John P. Saharek MBAChief Commercial Officer621.92kN/A1960
Mr. David MoufarrègeVP of TechnologyN/AN/AN/A
Jamie WebbDirector of Communications & Investor RelationsN/AN/AN/A
Dr. Dennis E Saadeh Pharm.D.Chief of Formulation StrategyN/AN/AN/A
Dr. Larry M. Dillaha M.D.Chief Medical OfficerN/AN/A1963
Mr. Andrew LivingstonChief Innovation OfficerN/AN/AN/A
Ms. Kim BarrattChief Talent OfficerN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and DEXYCU for the treatment of post-operative inflammation. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the development and commercialization of proprietary non-intravenous, sedation, and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings; and Eton Pharmaceuticals, Inc., a commercial-stage pharmaceutical company that engages in developing and commercializing drug products. Harrow Health, Inc. owns royalty rights in four clinical stage drug candidates being developed by Surface Ophthalmics, Inc. and Melt Pharmaceuticals, Inc. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Corporate Governance

Harrow Health, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Advertisement
Advertisement